Kwangdong Mepocitatin Tablets 50/500 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
MFDS item code 202200317 · Approved 2022.01.19
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used as an adjunct to improve blood sugar control in patients with type 2 diabetes. It should be administered alongside dietary management and exercise therapy, and is effective for patients who have not previously experienced diabetes drug therapy and have difficulty achieving blood sugar control with monotherapy. Additionally, it can be used as a substitute or in combination when adequate blood sugar control is not achieved with either metformin or sitagliptin as monotherapy. This medication can also be added to improve treatment effectiveness in cases where blood sugar control is insufficient with metformin and sulfonylurea, or combination therapy with metformin and thiazolidinedione. Furthermore, using this drug alongside insulin and metformin when blood sugar control is challenging can be beneficial. In summary, this medication improves blood sugar control in type 2 diabetes patients when used alone or in combination with various therapies.
The dose of this medication for antidiabetic therapy should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medication is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The starting dose of this medication should be based on the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior antidiabetic drug treatment whose blood glucose is not adequately controlled with monotherapy, or whose blood glucose cannot be adequately controlled with sitagliptin monotherapy, the starting dose is one tablet of this medication 50/500 mg twice daily. The dose may be increased to one tablet of this medication 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medication (see Precautions for Use, 2. Patients Who Must Not Take This Medication). 2. Patients receiving metformin: - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the recommended starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg) plus the patient's current metformin dose. - Patients switching to this medication from combination therapy with sitagliptin and metformin may start at their current doses of sitagliptin and metformin. 3. Patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The starting dose of this medication is sitagliptin 50 mg twice daily (total daily dose 100 mg). The starting dose of metformin should take into account the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this medication is used with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching to this medication in patients previously treated with another oral antihyperglycemic drug. Any change in the treatment regimen for type 2 diabetes may alter blood glucose control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used, with the following dose adjustment, in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate [eGFR] ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this medication should be discontinued immediately. Patients with hepatic impairment This medication should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medication).
This medication contains two active ingredients, sitagliptin and metformin, and is primarily used for blood sugar control in patients with type 2 diabetes. First, serious allergic reactions can occur during treatment with this medication; therefore, if symptoms such as rash, hives, difficulty breathing, or swelling of the face or throat occur, treatment should be discontinued immediately and a doctor should be consulted. Second, there is a risk of pancreatitis, an inflammation of the pancreas, so if severe abdominal pain, vomiting, or nausea occurs, medical personnel should be notified immediately. Third, the metformin component can, albeit rarely, cause a serious metabolic disorder known as lactic acidosis. If sudden breathing difficulties, muscle pain, fatigue, or abdominal pain occur, treatment should be discontinued immediately, and the patient should go to the hospital. Fourth, it is not safe for patients with impaired renal function, acute heart disease, severe infections, dehydration, liver dysfunction, or women who are pregnant or breastfeeding to take this medication. Fifth, if a surgical procedure is scheduled or if an examination involving radioactive iodine contrast is to be performed, the medication should be discontinued for a period before and after the examination, and it should only be resumed after confirming normal renal function. Sixth, this medication can cause hypoglycemia; therefore, patients should carefully monitor their blood sugar levels if meal quantities are irregular or inadequate, if they engage in rigorous exercise, or if they are taking other antidiabetic drugs. Seventh, while taking this medication, regular checks of kidney function and blood tests should be performed, and vitamin B12 levels should also be monitored periodically. Eighth, concurrent use of this medication with alcohol may increase the risk of lactic acidosis, so avoiding alcohol consumption is advised. Ninth, during treatment with this medication, if there are occurrences of blisters, severe skin rashes, or severe joint pain, patients should immediately inform medical personnel, and medication should be discontinued if needed. Finally, for elderly patients, it is essential to closely monitor renal function and to start at the minimum effective dosage while gradually adjusting as necessary.
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent air or moisture. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius.
Oval film-coated tablet in bright pink with '571' engraved on one side
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Kwangdong Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.